Citations

Clear

4610 citation(s) found for "Lu, Brian".

LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming
Ren, Bin , Best, Brad, Ramakrishnan, Devi Prasadh, Störz, Peter , Silverstein, Roy L. , Walcott, Brian P, Walcott, Brian Patrick

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 25, 2016 | Volume: 36 | Issue: 6 | Pages: 1197-1208

10.1161/atvbaha.116.307421 | PMID 27013613 Get It

Objective— CD36 is a scavenger and antiangiogenic receptor that is important in atherothrombotic diseases, diabetes mellitus, cancer, and obesity. Lysophosphatidic acid, a phospholipid signaling mediator, abolishes endothelial cell responses to antiangiogenic proteins containing thrombospondin type 1 homology domains by downregulating endothelial CD36 transcription via protein kinase D1 (PKD-1) signaling. We aimed to understand mechanisms by which lysophosphatidic acid–mediated angiogenic signaling is integrated to regulate CD36 transcription and endothelial cell function via a nuclear transcriptional complex. Approach and Results— Microvascular endothelial cells expressing CD36 were used for studying angiogenic signaling and CD36 transcription. Gene transfection and transduction, RT-qPCR, avidin–biotin-conjugated DNA-binding assay, chromatin immunoprecipitation assay, co-immunoprecipitation, proximal ligation assay, and immunofluorescence microscopy showed that lysophosphatidic acid–mediated CD36 transcriptional repression involved PKD-1 signaling mediated formation of forkhead box protein O1–histone deacetylase 7 complex in the nucleus. Unexpectedly, turning off CD36 transcription initiated reprogramming microvascular endothelial cells to express ephrin B2, a critical molecular signature involved in angiogenesis and arteriogenesis. Spheroid-based angiogenesis and in vivo Matrigel angiogenesis assays indicated that angiogenic branching morphogenesis and in vivo angiogenesis were dependent on PKD-1 signaling. A mouse tumor angiogenesis model revealed enhanced PKD-1 signaling and expression of ephrin B2 and smooth muscle actin in neovessels of Lewis Lung Carcinomas, along with low-CD36 expression or CD36 deficiency. Conclusions— Lysophosphatidic acid/PKD-1 signaling leads to nuclear accumulation of histone deacetylase 7, where it interacts with forkhead box protein O1 to suppress endothelial CD36 transcription and mediates silencing of antiangiogenic switch, resulting in proangiogenic and proarteriogenic reprogramming. Targeting this signaling cascade could be a novel approach for ischemic cardiovascular disease and cancer.
Gender‐specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states
Karpyak, Victor M. , Geske, Jennifer R. , Brunner, M. D., Chauhan, Mohit , Hall‐Flavin, Daniel K., Lewis, Kriste A., Loukianova, Larissa L., Melnyk, George J., Onsrud, David A., Proctor, Brian D., Schneekloth, Terry D. , Skime, Michelle , Wittkopp, John E., Frye, Mark A. , Mrazek, David A. , Abulseoud, Osama A. , Brunner, Michael D, Hall-Flavin, Daniel K, Skime, Michelle K., Biernacka, Joanna M. , Karpyak, Victor , Geske, Jennifer , Chauhan, Mohit

Mayo Clinic

Addiction | March 24, 2016 | Volume: 111 | Issue: 8 | Pages: 1366-1375

10.1111/add.13386 | PMID 27009547 Get It

Abstract Background and Aims Depression and anxiety are often comorbid with alcoholism and contribute to craving and relapse. We aimed to estimate the prevalence of life‐time diagnoses of major depressive disorder (MDD), substance‐induced depression (SID), anxiety disorder (AnxD) and substance‐induced anxiety (SIA), the effects of these comorbidities on the propensity to drink in negative emotional states (negative craving), and test whether these effects differ by sex. Design Secondary analyses of baseline data collected in a single‐arm study of pharmacogenetic predictors of acamprosate response. Setting Academic medical center and affiliated community‐based treatment programs in the American upper mid‐west. Participants A total of 287 males and 156 females aged 18–80 years, meeting DSM‐IV criteria for alcohol dependence. Measurements The primary outcome measure was ‘propensity to drink in negative emotional situations’ (determined by the Inventory of Drug Taking Situations) and the key predictors/covariates were sex and psychiatric comorbidities, including MDD, SID, AnxD and SIA (determined by Psychiatric Research Interview of Substance and Mood Disorders). Findings The prevalence of the MDD, SID and AnxD was higher in females compared with males (33.1 versus 18.4%, 44.8 versus 26.4% and 42.2 versus 27.4%, respectively; P < 0.01, each), while SIA was rare (3.3%) and did not differ by sex. Increased propensity to drink in negative emotional situations was associated with comorbid MDD (β = 6.6, P = 0.013) and AnxD (β = 4.8, P = 0.042) as well as a SID × sex interaction effect ( P = 0.003), indicating that the association of SID with propensity to drink in negative emotional situations differs by sex and is stronger in males (β = 7.9, P = 0.009) compared with females (β = −6.6, P = 0.091). Conclusions There appears to be a higher prevalence of comorbid depression and anxiety disorders as well as propensity to drink in negative emotional situations in female compared with male alcoholics. Substance‐induced depression appears to have a sex‐specific effect on the increased risk for drinking in negative emotional situations in males.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Sonneveld, Pieter , Avet‐Loiseau, Hervé , Usmani, Saad Z. , Moreau, Philippe , Attal, Michel , Kyle, Robert A. , Caers, Jo , Hillengaß, Jens , Miguel, Jesús F. San , Donk, Niels W.C.J. van de , Bladé, Joan , Durie, Brian G.M. , Goldschmidt, Hartmut , Mateos, María‐Victoria , Palumbo, Antonio , Orlowski, Robert Z. , Lonial, Sagar , Siegel, David S. , Anderson, Kenneth C. , Chng, Wee Joo , Einsele, Hermann , Orlowski, Robert Z. , Moreau, Philippe , San-Miguel, Jesus , Usmani, Saad

Mayo Clinic

Blood | March 22, 2016 | Volume: 127 | Issue: 24 | Pages: 2955-2962

10.1182/blood-2016-01-631200 | PMID 27002115 Get It

AbstractThe International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.
Long-Term Quality of Life and Functional Outcomes among Primary and Secondary Artificial Urinary Sphincter Implantations in Men with Stress Urinary Incontinence
Viers, Boyd R. , Linder, Brian J. , Rivera, Marcelino , Rangel, Laureano J. , Ziegelmann, Matthew , Elliott, Daniel S. , Rivera, Marcelino E, Ziegelmann, Matthew J, Linder, Brian J , Viers, Boyd R

Mayo Clinic

Journal of Urology | March 17, 2016 | Volume: 196 | Issue: 3 | Pages: 838-843

10.1016/j.juro.2016.03.076 | PMID 26997310 Get It

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Pratz, Keith W. , Koh, Brian D. , Patel, Anand G. , Flatten, Karen S., Poh, Weijie , Herman, James G. , Dilley, Robert L. , Harrell, Maria I., Karp, Judith E. , Swisher, Elizabeth M. , McDevitt, Michael A. , Kaufmann, Scott H. , Smith, B. Douglas , Swisher, Elizabeth M , Poh, Weijie

Mayo Clinic

Clinical Cancer Research | March 15, 2016 | Volume: 22 | Issue: 15 | Pages: 3894-3902

10.1158/1078-0432.ccr-15-2351 | PMID 26979391 Get It

Abstract Purpose: DNA repair defects have been previously reported in myeloproliferative neoplasms (MPN). Inhibitors of PARP have shown activity in solid tumors with defects in homologous recombination (HR). This study was performed to assess MPN sensitivity to PARP inhibitors ex vivo. Experimental Design: HR pathway integrity in circulating myeloid cells was evaluated by assessing the formation of RAD51 foci after treatment with ionizing radiation or PARP inhibitors. Sensitivity of MPN erythroid and myeloid progenitors to PARP inhibitors was evaluated using colony formation assays. Results: Six of 14 MPN primary samples had reduced formation of RAD51 foci after exposure to ionizing radiation, suggesting impaired HR. This phenotype was not associated with a specific MPN subtype, JAK2 mutation status, or karyotype. MPN samples showed increased sensitivity to the PARP inhibitors veliparib and olaparib compared with normal myeloid progenitors. This hypersensitivity, which was most pronounced in samples deficient in DNA damage–induced RAD51 foci, was observed predominantly in samples from patients with diagnoses of chronic myelogenous leukemia, chronic myelomonocytic leukemia, or unspecified myelodysplastic/MPN overlap syndromes. Conclusions: Like other neoplasms with HR defects, MPNs exhibit PARP inhibitor hypersensitivity compared with normal marrow. These results suggest that further preclinical and possibly clinical study of PARP inhibitors in MPNs is warranted. Clin Cancer Res; 22(15); 3894–902. ©2016 AACR.
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Dimopoulos, Meletios Α. , Sonneveld, Pieter , Merlini, Giampaolo , Kastritis, Efstathios , Goldschmidt, Hartmut , Joshua, Douglas, Orlowski, Robert Z. , Powles, Raymond, Vesole, David H., Garderet, Laurent, Palumbo, Antonio , Cavo, Michèle , Richardson, Paul G. , Moreau, Philippe , Miguel, Jesús F. San , Durie, Brian G.M. , Terpos, Evangelos , Bergsagel, P. Leif , Russell, Stephen J. , Rosiñol, Laura , Ocio, Enrique M. , García‐Sánz, Ramón , Beksaç, Meral , Zweegman, Sonja , Usmani, Saad Z. , Donk, Niels W.C.J. van de , Pratt, Guy , Chari, Ajai , Cook, Gordon , Rossi, Adriana , O’Dwyer, Michael , Paiva, Bruno , Larrea, Carlos Fernández de , Souza, Cármino Antônio De , Terragna, Carolina , Bergsagel, P. Leif , Dimopoulos, Meletios A, Ludwig, Heinz , San Miguel, Jesús, Leung, Nelson , Joshua, Douglas, Orlowski, Robert Z. , Einsele, Hermann , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Zweegman, Sonja , Merlini, Giampaolo , Dimopoulos, Meletios A , Russell, Stephen J , Moreau, Philippe , Terpos, Evangelos , Chari, Ajai , San-Miguel, Jesus , Paiva, Bruno , Kastritis, Efstathios , Garcia-Sanz, Ramon , Beksac, Meral , Cook, Gordon , Usmani, Saad , Rossi, Adriana , Ocio, Enrique M

Mayo Clinic

Journal of Clinical Oncology | March 14, 2016 | Volume: 34 | Issue: 13 | Pages: 1544-1557

10.1200/jco.2015.65.0044 | PMID 26976420 Get It

Purpose The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m 2 to 140 mg/m 2 ) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment
Schak, Kathryn M. , Voort, Jennifer L. Vande , Johnson, Emily K. , Kung, Simon , Leung, Jonathan G. , Rasmussen, Keith G., Palmer, Brian A. , Frye, Mark A. , Vande Voort, Jennifer L., Leung, Jonathan G

Mayo Clinic

American Journal of Psychiatry | March 1, 2016 | Volume: 173 | Issue: 3 | Pages: 215-218

10.1176/appi.ajp.2015.15081082 | PMID 26926127 Get It

Unique plasma metabolomic signatures of individuals with inherited disorders of long‐chain fatty acid oxidation
McCoin, Colin S. , Piccolo, Brian D. , Knotts, Trina A. , Matern, Dietrich , Gillingham, Melanie B. , Adams, Sean H. , Vockley, Jerry , Gillingham, Melanie B

Mayo Clinic

Journal of Inherited Metabolic Disease | February 23, 2016 | Volume: 39 | Issue: 3 | Pages: 399-408

10.1007/s10545-016-9915-3 | PMID 26907176 Get It

AbstractBlood and urine acylcarnitine profiles are commonly used to diagnose long‐chain fatty acid oxidation disorders (FAOD: i.e., long‐chain hydroxy‐acyl‐CoA dehydrogenase [LCHAD] and carnitine palmitoyltransferase 2 [CPT2] deficiency), but the global metabolic impact of long‐chain FAOD has not been reported. We utilized untargeted metabolomics to characterize plasma metabolites in 12 overnight‐fasted individuals with FAOD (10 LCHAD, two CPT2) and 11 healthy age‐, sex‐, and body mass index (BMI)‐matched controls, with the caveat that individuals with FAOD consume a low‐fat diet supplemented with medium‐chain triglycerides (MCT) while matched controls consume a typical American diet. In plasma 832 metabolites were identified, and partial least squared‐discriminant analysis (PLS‐DA) identified 114 non‐acylcarnitine variables that discriminated FAOD subjects and controls. FAOD individuals had significantly higher triglycerides and lower specific phosphatidylethanolamines, ceramides, and sphingomyelins. Differences in phosphatidylcholines were also found but the directionality differed by metabolite species. Further, there were few differences in non‐lipid metabolites, indicating the metabolic impact of FAOD specifically on lipid pathways. This analysis provides evidence that LCHAD/CPT2 deficiency significantly alters complex lipid pathway flux. This metabolic signature may provide new clinical tools capable of confirming or diagnosing FAOD, even in subjects with a mild phenotype, and may provide clues regarding the biochemical and metabolic impact of FAOD that is relevant to the etiology of FAOD symptoms.
Outcomes of artificial urinary sphincter placement in octogenarians
Ziegelmann, Matthew , Linder, Brian J. , Rivera, Marcelino , Viers, Boyd R. , Rangel, Laureano J. , Elliott, Daniel S. , Ziegelmann, Matthew J, Rivera, Marcelino E, Linder, Brian J , Viers, Boyd R

Mayo Clinic

International Journal of Urology | February 18, 2016 | Volume: 23 | Issue: 5 | Pages: 419-423

10.1111/iju.13062 | PMID 26890355 Get It

ObjectiveTo evaluate the impact of patient age on device outcomes among patients undergoing primary artificial urinary sphincter.MethodsA total of 1081 male patients who underwent primary artificial urinary sphincter placement from 1983 to 2011 were analyzed, including 91 men (8%) who were aged >80 years at the time of surgery. Revisions and explanations were compared between men stratified by decade of life. Hazard ratios adjusting for competing risks were used to determine the association with age and artificial urinary sphincter device outcomes (infection/erosion, urethral atrophy and malfunction), while overall device failure was estimated using Kaplan–Meier and Cox regression analysis.ResultsPatients aged >80 years were more likely to have coronary disease (P = 0.009), diabetes mellitus (P = 0.04), hypertension (P = 0.002) and lower body mass index (P < 0.0001). On multivariable analysis, patients aged >80 years were significantly more likely to experience device erosion or infection compared with a reference of patients aged <60 years (hazard ratio 4.13; P = 0.046), whereas there was no difference in those patients aged 60–70 years or 70–80 years compared with the reference group (P = 0.56 and 0.45). There was no significant difference in overall device survival between the age‐stratified groups (P = 0.26).ConclusionsAlthough overall artificial urinary sphincter device survival is similar, patients aged >80 years are more likely to experience erosion or infection compared with younger patients. Despite this, the overall device failure rate is low, and artificial urinary sphincter might be considered for appropriately selected and counseled octogenarians.
Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum
Flanagan, Eoin P. , Cabre, Philippe, Weinshenker, Brian G. , Sauver, Jennifer L. St. , Jacobson, Debra J., Majed, Masoud , Lennon, Vanda A. , Lucchinetti, Claudia F. , McKeon, Andrew , Matiello, Marcelo , Kale, Nilifur, Wingerchuk, Dean M. , Mandrekar, Jay , Sagen, Jessica, Fryer, James P., Robinson, Angala Borders, Pittock, Sean J. , Sagen, Jessica A., Pittock, S J , Flanagan, E P , Weinshenker, Brian G , St Sauver, Jennifer L , McKeon, Andrew

Mayo Clinic

Annals of Neurology | February 18, 2016 | Volume: 79 | Issue: 5 | Pages: 775-783

10.1002/ana.24617 | PMID 26891082 Get It

ObjectiveNeuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDDs) with a specific biomarker, aquaporin‐4–immunoglobulin G (AQP4‐IgG). Prior NMO/NMOSD epidemiological studies have been limited by lack of AQP4‐IgG seroprevalence assessment, absence of population‐based USA studies, and under‐representation of blacks. To overcome these limitations, we sought to compare NMO/NMOSD seroepidemiology across 2 ethnically divergent populations.MethodsWe performed a population‐based comparative study of the incidence (2003–2011) and prevalence (on December 31, 2011) of NMO/NMOSD and AQP4‐IgG seroincidence and seroprevalence (sera collected in 80–84% of IDD cases) among patients with IDD diagnosis in Olmsted County, Minnesota (82% white [Caucasian]) and Martinique (90% black [Afro‐Caribbean]). AQP4‐IgG was measured by M1 isoform fluorescence‐activated cell‐sorting assays.ResultsThe age‐ and sex‐adjusted incidence (7.3 vs 0.7/1,000,000 person‐years [p < 0.01]) and prevalence (10 vs 3.9/100,000 [p = 0.01]) in Martinique exceeded that in Olmsted County. The AQP4‐IgG age‐ and sex‐adjusted seroincidence (6.5 vs 0.7/1,000,000 person‐years [p < 0.01]) and seroprevalence (7.9 vs 3.3/100,000 [p = 0.04]) were also higher in Martinique than Olmsted County. The ethnicity‐specific prevalence was similar in Martinique and Olmsted County: 11.5 and 13/100,000 in blacks, and 6.1 and 4.0/100,000 in whites, respectively. NMO/NMOSD represented a higher proportion of IDD cases in Martinique than Olmsted County (16% vs 1.4%; p < 0.01). The onset age (median = 35–37 years) and female:male distribution (5–9:1) were similar across both populations; 60% of prevalent cases were either blind in 1 eye, dependent on a gait aid, or both.InterpretationThis study reports the highest prevalence of NMO/NMOSD in any population (10/100,000 in Martinique), estimates it affects 16,000 to 17,000 in the USA (higher than previous predictions), and demonstrates it disproportionately affects blacks. Ann Neurol 2016;79:775–783